A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01)
Jianghao Chen; Qing Yao; Meiling Huang; Bo Wang; Juliang Zhang; Ting Wang; Yu Ming; Xiaodong Zhou; Qianxin Jia; Yi Huan; Jing Wang; Ling Wang
Author Information: Department of Thyroid, Breast and Vascular Surgery
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.